Actuate Therapeutics, Inc.
ACTU
$7.35
-$0.08-1.08%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.52M | 10.86M | 8.72M | 6.48M | 4.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.37M | 24.29M | 23.75M | 25.16M | 26.22M |
| Operating Income | -24.37M | -24.29M | -23.75M | -25.16M | -26.22M |
| Income Before Tax | -24.12M | -24.68M | -25.31M | -27.29M | -28.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.12 | -24.68 | -25.31 | -27.29 | -28.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.12M | -24.68M | -25.31M | -27.29M | -28.45M |
| EBIT | -24.37M | -24.29M | -23.75M | -25.16M | -26.22M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.21 | -1.51 | -5.41 | -10.49 | -15.22 |
| Normalized Basic EPS | -0.76 | -0.90 | -2.97 | -5.94 | -8.90 |
| EPS Diluted | -1.21 | -1.51 | -5.41 | -10.49 | -15.22 |
| Normalized Diluted EPS | -0.76 | -0.90 | -2.97 | -5.94 | -8.90 |
| Average Basic Shares Outstanding | 80.09M | 69.47M | 51.39M | 33.42M | 15.38M |
| Average Diluted Shares Outstanding | 80.09M | 69.47M | 51.39M | 33.42M | 15.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |